Evidence map›Paper›PMID 38932307›Full record

ArticleVaccines2024

Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403.

Diogo Gama Caetano, Thais Stelzer Toledo, Ana Carolina Souza de Lima, Carmem Beatriz Wagner Giacoia-Gripp, Dalziza Victalina de Almeida, Sheila Maria Barbosa de Lima, Adriana de Souza Azevedo, Michelle Morata, Beatriz Grinsztejn, Sandra Wagner Cardoso and 6 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Diogo Gama CaetanoLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0002-8889-0655
Thais Stelzer ToledoLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Ana Carolina Souza de LimaLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Carmem Beatriz Wagner Giacoia-GrippLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Dalziza Victalina de AlmeidaLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0003-0917-0009
Sheila Maria Barbosa de LimaDepartamento de Desenvolvimento Experimental e Pré-Clínico (DEDEP), Bio-Manguinhos/Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-9234-1678
Adriana de Souza AzevedoLaboratório de Análise Imunomolecular (LANIM), Bio-Manguinhos/Fiocruz, Rio de Janeiro 21040-900, Brazil.ORCID 0000-0001-7401-5107
Michelle MorataInstituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Beatriz GrinsztejnInstituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Sandra Wagner CardosoInstituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Marcellus Dias da CostaLaboratório de Pesquisa em Imunização e Vigilância em Saúde (LIVS), Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Luciana Gomes Pedro BrandãoLaboratório de Pesquisa em Imunização e Vigilância em Saúde (LIVS), Instituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Ana Maria Bispo de FilippisLaboratório de Flavivírus, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.
Daniel Scott-AlgaraLymphocyte Cell Biology Unit, Pasteur Institute, 75015 Paris, France.ORCID 0000-0003-1851-503X
Lara Esteves CoelhoInstituto Nacional de Infectologia Evandro Chagas/Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0001-7154-8151
Fernanda Heloise CôrtesLaboratório de AIDS e Imunologia Molecular, Instituto Oswaldo Cruz/Fiocruz, Rio de Janeiro 21040-360, Brazil.ORCID 0000-0003-1416-0657

Funding

The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
Agence Nationale de Recherches sur le Sida et les Hépatites Virales Project 12403NIAID NIH HHS UM1 AI069476Presidência da Fundação Oswaldo Cruz/ Vice-presidência de Pesquisa e Coleções Biológicas VPPCB/Fiocruz Chamada CNPq/Fiocruz N8 16/2017 PROEP/PEC / #420674/2017-9
6 · The paper itself

Abstract

The yellow fever (YF) vaccine is one of the safest and most effective vaccines currently available. Still, its administration in people living with HIV (PLWH) is limited due to safety concerns and a lack of consensus regarding decreased immunogenicity and long-lasting protection for this population. The mechanisms associated with impaired YF vaccine immunogenicity in PLWH are not fully understood, but the general immune deregulation during HIV infection may play an important role. To assess if HIV infection impacts YF vaccine immunogenicity and if markers of immune deregulation could predict lower immunogenicity, we evaluated the association of YF neutralization antibody (NAb) titers with the pre-vaccination frequency of activated and exhausted T cells, levels of pro-inflammatory cytokines, and frequency of T cells, B cells, and monocyte subsets in PLWH and HIV-negative controls. We observed impaired YF vaccine immunogenicity in PLWH with lower titers of YF-NAbs 30 days after vaccination, mainly in individuals with CD4 count <350 cells/mm

Indexed as

B cellsHIV-1immune activationimmune exhaustioninflammationyellow fever vaccine

Identifiers

PMID38932307
PMCPMC11209244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.